“Although we recognize there is still much work to be done, MassBio is incredibly encouraged about the early results from the Pfizer/BioNTech trials. The unprecedented speed with which the biopharma industry is developing COVID-19 tests, treatments, and vaccines is a testament to the industry’s commitment to addressing our world’s most dire healthcare needs. It’s also a reminder of the critical role it plays in the health and wellbeing of our country and economy and we should all celebrate the scientific progress and innovation we’ve seen in the last nine months.”
– Robert K. Coughlin, President & CEO, MassBio